Hay S - Search Results

1

Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males.

Findlay D, Chehade M, Tsangari H, Neale S, Hay S, Hopwood B, Pannach S, O'Loughlin P, Fazzalari N. Findlay D, et al. Among authors: hay s. Arthritis Res Ther. 2008;10(1):R2. doi: 10.1186/ar2348. Epub 2008 Jan 8. Arthritis Res Ther. 2008. PMID: 18182105 Free PMC article.

2

Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.

Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM. Evdokiou A, et al. Among authors: hay s. Int J Cancer. 2002 Jun 1;99(4):491-504. doi: 10.1002/ijc.10376. Int J Cancer. 2002. PMID: 11992538 Free article.

3

Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.

Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V, Diamond P, Findlay DM, Zannettino AC, Evdokiou A. Zinonos I, et al. Among authors: hay s. J Bone Miner Res. 2011 Mar;26(3):630-43. doi: 10.1002/jbmr.244. J Bone Miner Res. 2011. PMID: 20818644 Free PMC article.

4

Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.

Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM. Atkins GJ, et al. Among authors: hay s. J Bone Miner Res. 2000 Apr;15(4):640-9. doi: 10.1359/jbmr.2000.15.4.640. J Bone Miner Res. 2000. PMID: 10780856 Free article.

5

Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.

Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino AC, Hay S, Findlay DM. Atkins GJ, et al. Among authors: hay s. Bone. 2001 Apr;28(4):370-7. doi: 10.1016/s8756-3282(01)00404-5. Bone. 2001. PMID: 11336917

6

Peroxidase enzymes inhibit osteoclast differentiation and bone resorption.

Panagopoulos V, Liapis V, Zinonos I, Hay S, Leach DA, Ingman W, DeNichilo MO, Atkins GJ, Findlay DM, Zannettino ACW, Evdokiou A. Panagopoulos V, et al. Among authors: hay s. Mol Cell Endocrinol. 2017 Jan 15;440:8-15. doi: 10.1016/j.mce.2016.11.007. Epub 2016 Nov 9. Mol Cell Endocrinol. 2017. PMID: 27836774

7

Expression of fibrillins and other microfibril-associated proteins in human bone and osteoblast-like cells.

Kitahama S, Gibson MA, Hatzinikolas G, Hay S, Kuliwaba JL, Evdokiou A, Atkins GJ, Findlay DM. Kitahama S, et al. Among authors: hay s. Bone. 2000 Jul;27(1):61-7. doi: 10.1016/s8756-3282(00)00292-1. Bone. 2000. PMID: 10865210

8

Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.

Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A. Thai le M, et al. Among authors: hay s. Cancer Res. 2006 May 15;66(10):5363-70. doi: 10.1158/0008-5472.CAN-05-4386. Cancer Res. 2006. PMID: 16707463

9

Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma.

Labrinidis A, Diamond P, Martin S, Hay S, Liapis V, Zinonos I, Sims NA, Atkins GJ, Vincent C, Ponomarev V, Findlay DM, Zannettino AC, Evdokiou A. Labrinidis A, et al. Among authors: hay s. Clin Cancer Res. 2009 Mar 15;15(6):1998-2009. doi: 10.1158/1078-0432.CCR-08-2444. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276263 Free PMC article.

10

Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.

Labrinidis A, Hay S, Liapis V, Findlay DM, Evdokiou A. Labrinidis A, et al. Among authors: hay s. Int J Cancer. 2010 Jul 15;127(2):345-54. doi: 10.1002/ijc.25051. Int J Cancer. 2010. PMID: 19924813 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,188 results

Search Page